ClinicalTrials.gg
Not yet recruitingNCT05589454Updated Oct 21, 2022

Intracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds

A Phase 4 interventional study of Atorvastatin Calcium tablets 80mg and Atorvastatin Calcium tablets 20mg in Acute Ischemic Stroke and Cerebral Microbleeds, sponsored by Sichuan Provincial People's Hospital. Not yet recruiting at 5 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-10-21.

Sponsored by Sichuan Provincial People's Hospital · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
241st of 566
344 · median 271
Started
2023
with 91 others
Phase 4
70 of 754
31 open now
Primary completion
2026-12
later than 153 of 399 live
Registered
296th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 241st largest by planned enrollment of the 566 interventional ones that give a count, is one of 92 that started in 2023, is one of 70 in phase 4, reaches primary completion later than 153 of the 399 other live ones, and was the 296th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This study is the first and largest secondary prevention trial about lipid-lowering therapy for acute ischemic stroke patients at high-risk of intracranial hemorrhage.

The primary hypothesis of this study is: excessive reduction in serum lipid levels by intensive statin therapy in acute ischemic stroke patients with cerebral microbleeds can increase the risk of intracranial hemorrhage.

This study will shed light on new clinical decisions regarding the long-term serum lipid management in these patients with dilemma in clinical practice.

Read the detailed description

Cerebral microbleeds are an important subtype of cerebral small vessel diseases that have been established in approximately one third of patients with ischemic stroke and are associated with the risk of recurrent ischemic stroke, symptomatic intracranial hemorrhage, and all-cause death. In patients with ischemic stroke or transient ischemic attack, the relative and absolute risks of intracranial hemorrhage increase more rapidly than the risk of ischemic stroke with the increase of cerebral microbleeds burden, but the absolute incidence of ischemic stroke is still higher than that of cerebral hemorrhage.

It has been generally accepted that statins can effectively prevent recurrent ischemic stroke by reducing serum lipid levels. However, both low serum lipid levels and high dose of statins are clear risk factors for intracerebral hemorrhage, and the reduction of major serum lipid levels may increase the risk of cerebral microbleeds. Of note, the risk of statin mediated hemorrhage appears to depend on the degree of lipid reduction rather than statin use per se. These observations raise concerns about the safety of lipid-lowering therapy, especially intensive lipid-lowering therapy, in patients with acute ischemic stroke and cerebral microbleeds who are at high risk for future intracranial hemorrhage. It is still not clear that how to carry on the proper management of serum lipid levels in this particular population to reduce the recurrence of ischemic events as well as hemorrhagic events, for there is still a lack of clinical studies to explore the risk and benefit of different doses of statins to achieve different degrees of lipid regulation.

So, if it is proved that excessive reduction in serum lipid levels by intensive statin therapy in acute ischemic stroke patients with cerebral microbleeds can increase the risk of future intracranial hemorrhage, we will inform new clinical decisions regarding the long-term lipid management in these patients with dilemma in clinical practice.

03

Conditions studied

  • Acute Ischemic Stroke
  • Cerebral Microbleeds

Browse trials for

Keywords

  • Acute Ischemic Stroke
  • Intracranial Hemorrhage Risk
  • Cerebral Microbleeds
  • Intensive Statin Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a non-cardioembolic ischemic stroke within 14 days prior to entry to the study
  2. Adults between the ages of 18 and 85
  3. Patients with cerebral microbleeds on baseline SWI imaging
  4. Patients or their legal representatives volunteer to participate and sign written

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe acute ischemic stroke (NIHSS score ≥21)
  2. Patients with coma (GCS score \< 8)
  3. Patients with previous moderate to severe dependence (mRS score 3-5)
  4. Patients with any to CT and MRI (such as metal implants, claustrophobia, etc.)
  5. Patients who are allergic to atorvastatin or
  6. Patients with intracranial hemorrhagic diseases confirmed by CT or MRI, such as cerebral hemorrhage, epidural hematoma, subdural hematoma, ventricular hemorrhage, subarachnoid hemorrhage, traumatic cerebral hemorrhage or hemorrhagic conversion of infarcts, etc
  7. Patients within 6 months after hemorrhagic stroke
  8. Patients with hemorrhagic tendency, such as abnormal coagulation function, Henoch-Schonlein purpura, count less than 100×109/L or abnormal platelet function, etc
  9. Patients who are ready to undergo or have undergone intravenous thrombolysis after the onset of the disease or who require urgent or recent (within 90 days) endovascular treatment;
  10. Patients with severe hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that has not been controlled by treatment
  11. Patients with hypoglycemia (\< 2.7 mmol/L) or hyperglycemia (>22.2 mmol/L)
  12. Patients with previous cerebral arteritis, brain tumor, cerebral parasitic disease, cerebral arteriovenous malformation, cerebral cavernous hemangioma, cerebral aneurysm, severe craniocerebral injury, or intracranial infection
  13. Patients with previous severe valvular heart disease, atrial fibrillation, acute myocardial infarction or interventional therapy in the past 6 months, heart failure (patients classified as class III-IV according to the [NYHA]) or patients with indications for pacemaker placement but without pacemaker installation or other malignant arrhythmias
  14. Patients contraindicate to antiplatelet therapy;
  15. Patients who must use other types of statins or other types of lipid-lowering drugs such as ezetimibe
  16. Patients with severe mental disorders or dementia that are unable or unwilling to cooperate
  17. Patients with active liver disease or unexplained 2 or more abnormal liver function tests ( [ALT] or aspartate aminotransferase [AST] ≥ 3.0× [ULN])
  18. Patients with myositis, myopathy, rhabdomyolysis, or 2 or more episodes of unexplained serum creatine kinase[CK] elevation ([CK]≥5.0×ULN)
  19. Patients with other serious systemic or organic diseases that investigators believe will not allow evaluation of efficacy or are unlikely to complete the expected course of treatment and follow-up (e.g., , \< 3 years, etc.)
  20. Women who are pregnant, breastfeeding or planning to become pregnant and who do not want to use
  21. Patients who participated in or are participating in other clinical trials during the 3 months prior to the study
  22. Patients who are deemed ineligible for clinical trial participation by the investigator
  23. Patients or their legal representatives do not consent to participate in this study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
344 participants (estimated)

Study arms

  • Experimental
    High-dose atorvastatin

    atorvastatin calcium tablets 80 mg, quaque nocte, continue to the end of the study

    Drug: Atorvastatin Calcium tablets 80mg

  • Active comparator
    Low-dose atorvastatin

    atorvastatin calcium tablets 20 mg, quaque nocte, continue to the end of the study

    Drug: Atorvastatin Calcium tablets 20mg

Interventions

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up

    Also known as: ALe produced by Jialin pharmaceutical company

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up

    Also known as: ALe produced by Jialin pharmaceutical company

06

What researchers measure

Primary outcomes

  1. The incidence of hemorrhagic strokes

    Time frame: From date of randomization until the date of the first occurrence of hemorrhagic stroke, assessed up to 36 months

  2. Changes in degree of cerebral microbleeds

    The degree is divided into: mild (1-2), moderate (3-10), severe (more than 10), calculate and compare the proportions of different degrees at baseline and the end of the study

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

Secondary outcomes

  1. The Incidence of recurrent ischemic stroke and transient ischemic attack

    Time frame: From date of randomization until the date of the first recurrent of ischemic stroke or the first occurrence of transient ischemic attack, assessed up to 36 months

  2. The Incidence of myocardial infarction

    Time frame: From date of randomization until the date of the first occurrence of myocardial infarction, assessed up to 36 months

  3. The Incidence of cardiovascular death

    Time frame: From date of randomization until the date of cardiovascular death, assessed up to 36 months

  4. The mean of serum triglycerides (TG) levels

    Calculate the mean of serum TG levels for 3 years with at least 3 measurements

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  5. The mean of serum total cholesterol (TC) levels

    Calculate the mean of serum TC levels for 3 years with at least 3 measurements

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  6. The mean of serum low-density lipoprotein cholesterol (LDL-C) levels

    Calculate the mean of serum LDL-C levels for 3 years with at least 3 measurements

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  7. The mean of serum high-density lipoprotein cholesterol (HDL-C) levels

    Calculate the mean of serum HDL-C levels for 3 years with at least 3 measurements

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  8. The variability of serum triglycerides (TG) levels

    Calculate the variability of serum TG levels for 3 years with at least 3 measurements

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  9. The variability of serum total cholesterol (TC) levels

    Calculate the variability of serum TC levels for 3 years with at least 3 measurements

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  10. The variability of serum low-density lipoprotein cholesterol (LDL-C) levels

    Calculate the variability of serum LDL-C levels for 3 years with at least 3 measurements

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  11. The variability of serum high-density lipoprotein cholesterol (HDL-C) levels

    Calculate the variability of serum HDL-C levels for 3 years with at least 3 measurements

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  12. The proportions of different degrees of CMBs at the end of the study

    Calculate the proportions of different degrees of CMBs (mild, moderate and severe) at the end of the study

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  13. The correlation between the mean of serum triglycerides (TG) levels and the proportions of different degrees of CMBs

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  14. The correlation between the mean of serum total cholesterol (TC) levels and the proportions of different degrees of CMBs

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  15. The correlation between the mean of serum low-density lipoprotein cholesterol (LDL-C) levels and the proportions of different degrees of CMBs

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  16. The correlation between the mean of serum high-density lipoprotein cholesterol (HDL-C) levels and the proportions of different degrees of CMBs

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  17. The correlation between the variability of serum triglycerides (TG) levels and the proportions of different degrees of CMBs

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  18. The correlation between the variability of serum total cholesterol (TC) levels and the proportions of different degrees of CMBs

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  19. The correlation between the variability of serum low-density lipoprotein cholesterol (LDL-C) levels and the proportions of different degrees of CMBs

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

  20. The correlation between the variability of serum high-density lipoprotein cholesterol (HDL-C) levels and the proportions of different degrees of CMBs

    Time frame: From date of randomization until the end of the study, assessed up to 36 months

07

Study locations

5 sites
  • Yunyang County People's Hospital
    Chongqing, Chongqing 404599, China
  • Chengdu Eighth People's Hospital
    Chengdu, Sichuan 610017, China
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
  • Ya 'an People's Hospital
    Ya'an, Sichuan 625000, China
  • Zigong Third People's Hospital
    Zigong, Sichuan 643021, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2023; primary completion for Dec 2026, 47 months later.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 47 months is above that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2022
First posted
Oct 21, 2022
StartEst.
Jan 2023
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Oct 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05589454
Lead sponsor
Sichuan Provincial People's Hospital
Collaborators
Science and Technology Department of Sichuan Province
Responsible party
Jialing Zhao (Principal Investigator, Sichuan Provincial People's Hospital) — Principal investigator
First posted
Oct 21, 2022
Start date
Jan 2023 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 21, 2022

Study contacts

Jialing Zhao, MD
Contact
jailynyy@163.com
+8618113137196
Jialing Zhao, MD
principal investigator · Departement of Neurology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Yang Xiang, MD
study director · Departement of Neurology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion